newsfilter
← Latest News
Business Wire·

Phase III FIND‑CKD Results Show Bayer's KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease

Investigational results from FIND-CKD provide full efficacy and safety data and is the fifth consecutive Phase III clinical trial where KERENDIA met its primary endpoint—adding to a clinical trial program of more than